Louisiana 2019 2019 Regular Session

Louisiana House Bill HB571 Comm Sub / Analysis

                    DIGEST
The digest printed below was prepared by House Legislative Services.  It constitutes no part of the
legislative instrument.  The keyword, one-liner, abstract, and digest do not constitute part of the law
or proof or indicia of legislative intent.  [R.S. 1:13(B) and 24:177(E)]
HB 571 Engrossed	2019 Regular Session	Seabaugh
Abstract:  Allows healthcare providers who purchase plastic and metallic implants or non-
autogenous grafts to be reimbursed for reasonable cost of the implants.
Present law provides that the assistant secretary of the office of workers' compensation shall establish
and promulgate a reimbursement schedule for drugs, supplies, hospital care and services, medical
and surgical treatment, and any non-medical treatment recognized by present law, the Workers'
Compensation Act. 
Proposed law retains present law to add that the facility, hospital or ambulatory surgery center, must
order and pay for the implant or non-autogenous graft and upon receipt of the original manufacturer's
invoice, shall be reimbursed by the payor, in accordance with the specifications of the surgeon
regarding the type, number, and manufacturer of the implant. 
Proposed law provides that the reimbursed amount shall be at the manufacturer's original invoice
amount, exclusive of rebates and discounts, plus 20%. 
(Adds R.S. 23:1203.1.2)
Summary of Amendments Adopted by House
The Committee Amendments Proposed by House Committee on Labor and Industrial Relations
to the original bill:
1. Add that the facility, hospital, or ambulatory surgery center shall be reimbursed by the
payor in accordance with the specifications of the surgeon including the type, number,
and manufacturer of the implant. 
2. Remove the requirement that the costs associated with the purchasing of an implant or
non-autogenous graft not exceed what a prudent buyer pays for an item or service of its
kind. 
3. Remove the requirement that if costs of the implant or non-autogenous graft should
exceed the level of a prudent buyer then the amount in excess not be reimbursed.